fbpx

Insulet to Unveil New Omnipod DASHTM System and Present Innovative Research at the American Diabetes Association’s 78th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced it will showcase its
recently FDA cleared Omnipod DASHTM Insulin Management System
(Omnipod DASH System), during the American
Diabetes Association (ADA) 78th Scientific Sessions at
the Orange County Convention Center in Orlando, Florida June 22-25,
2018. Insulet will also have a robust clinical presence at the meeting
with 10 accepted abstracts, including six posters and three oral
presentations.

Insulet’s largest presence to date will feature its new, innovative
Omnipod DASH System in a product theater, a variety of hands-on,
interactive product demonstrations, and other events during the show and
at its exhibit booth (#1603). The Company will also present new research
results for its innovation pipeline, including the Omnipod Horizon™
Automated Glucose Control (Omnipod Horizon) System and the use of
concentrated insulin in the Omnipod System, as well as additional data
further supporting the benefits of the Omnipod System. For the second
consecutive year, Omnipod Horizon System research was selected to be
highlighted in the official ADA Press Program based upon its overall
excellence in furthering research and advancing treatment for people
with diabetes.

“This is truly an exciting time for Insulet,” said Shacey Petrovic,
President and Chief Operating Officer. “We are committed to delivering
innovative new products to the diabetes community with the upcoming
launch of our new Omnipod DASH System. We are also pleased to present
new research demonstrating the significant progress we are making on our
robust innovation roadmap.”

A schedule of Insulet clinical presentations at ADA is as follows:

65-OR Reducing basal insulin 90 minutes before exercise
protects against hypoglycemia better than insulin suspension at
exercise onset in T1D: The OmniTIME Results

 

Dessi Zaharieva, Sarah M. McGaugh, Rubin Pooni, Todd Vienneau,
Trang T. Ly, Michael Riddell

1695-P Reduced Rate of Acute Complications with Tubeless
Insulin Pump Use: Data from 2,640 Patients in the German/Austrian
DPV Registry

 

Torben Biester, Thomas Danne, Esther Bollow, Anke Schwandt,
Bettina Heidtmann, Birgit Rami-Merhar, Thomas Haak, Reinhard W.
Holl

1011-P Human Regular U-500 Insulin via Continuous Subcutaneous
Insulin Infusion vs. Multiple Daily Injections in Adults with T2D:
the VIVID Study—Primary Population

 

George Grunberger, Anuj Bhargava, Trang T. Ly, Howard Zisser, Liza
Ilag, James K. Malone, Shuyu Zhang, Jennal Johnson

1038-P Pharmacokinetics and Pharmacodynamics of Human Regular
U-500 Insulin (U-500R) Administered via Continuous Subcutaneous
Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults
with Type 2 Diabetes and High Insulin Requirements

 

Xiaosu Ma, Randy P. Prescilla, Shuyu Zhang, Helle Linnebjerg,
Linda Morrow, Jeffrey A. Jackson, Jennal Johnson, Derek Leishman

967-P Patient Reported Outcomes (PRO) in a Study of Human
Regular U-500 Insulin (U-500R) Delivered by Continuous
Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections
(MDI) in Patients with T2D

 

Xiaomei Peng, Jieling Chen, Ludi Fan, Liza Ilag, Trang T. Ly,
Jennal Johnson

207-OR Safety and Performance of the Omnipod®
Hybrid Closed-Loop System in Adults with Type 1 Diabetes Over Five
Days Under Free-Living Conditions

 

Bruce A. Buckingham, Jennifer L. Sherr, Gregory P. Forlenza,
Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais,
Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly

1376-P Safety and Performance of the Omnipod®
Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes Over
Five Days Under Free-Living Conditions

 

Gregory P. Forlenza, Bruce A. Buckingham, Jennifer L. Sherr,
Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais,
Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly

1377-P Safety and Performance of the Omnipod®
Hybrid Closed-Loop System in Children with Type 1 Diabetes Over
Five Days Under Free-Living Conditions

 

Jennifer L. Sherr, Gregory P. Forlenza, Bruce A. Buckingham,
Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais,
Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly

351-OR Human Regular U-500 Insulin via Continuous Subcutaneous
Insulin Infusion vs. Multiple Daily Injections in Adults with T2D:
the VIVID Study—All Randomized Population

 

George Grunberger, Anuj Bhargava, Trang T. Ly, Howard Zisser, Liza
Ilag, James K. Malone, Shuyu Zhang, Jennal Johnson

2274-PUB Long-term Use of Omnipod®
Insulin Management System Associated with Lower A1c in Adults with
Established Diabetes and A1c ?8%

 

Liane J. Tinsley, Lori M. Laffel, Zijing Guo, Nisha Naik, Jennifer
E. Layne, Trang T. Ly, Sanjeev N. Mehta

1 The Pod has a waterproof IPX8 rating for up to 25
feet for 60 minutes. The PDM is not waterproof.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its Pod, by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, more than 140,000 users across the globe rely on
Insulet’s Omnipod Insulin Management System to bring simplicity and
freedom to their lives. For more information, please visit: www.insulet.com,
www.myomnipod.com
and www.omnipodeurope.com.*

*Starting July 1, 2018, Insulet will assume direct distribution of its
Omnipod Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This will allow Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it already does in the
United States and Canada.

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet’s expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
“Risk Factors,” and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. DASH, Horizon, Omnipod and the Omnipod logo
are trademarks or registered trademarks of Insulet Corporation. All
rights reserved. The Bluetooth® word mark and logos are
registered trademarks owned by the Bluetooth SIG, Inc. and any use of
such marks by Insulet Corporation is under license.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005199/en/